Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population
- PMID: 29100191
- DOI: 10.1016/j.ejca.2017.09.031
Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population
Abstract
Background: PREDICT version 2.0 is increasingly used to estimate prognosis in breast cancer. This study aimed to validate this tool in specific prognostic subgroups in the Netherlands.
Methods: All operated women with non-metastatic primary invasive breast cancer, diagnosed in 2005, were selected from the nationwide Netherlands Cancer Registry (NCR). Predicted and observed 5- and 10-year overall survival (OS) were compared for the overall cohort, separated by oestrogen receptor (ER) status, and predefined subgroups. A >5% difference was considered as clinically relevant. Discriminatory accuracy and goodness-of-fit were determined using the area under the receiver operating characteristic curve (AUC) and the Chi-squared-test.
Results: We included 8834 patients. Discriminatory accuracy for 5-year OS was good (AUC 0.80). For ER-positive and ER-negative patients, AUCs were 0.79 and 0.75, respectively. Predicted 5-year OS differed from observed by -1.4% in the entire cohort, -0.7% in ER-positive and -4.9% in ER-negative patients. Five-year OS was accurately predicted in all subgroups. Discriminatory accuracy for 10-year OS was good (AUC 0.78). For ER-positive and ER-negative patients AUCs were 0.78 and 0.76, respectively. Predicted 10-year OS differed from observed by -1.0% in the entire cohort, -0.1% in ER-positive and -5.3 in ER-negative patients. Ten-year OS was overestimated (6.3%) in patients ≥75 years and underestimated (-13.%) in T3 tumours and patients treated with both endocrine therapy and chemotherapy (-6.6%).
Conclusions: PREDICT predicts OS reliably in most Dutch breast cancer patients, although results for both 5-year and 10-year OS should be interpreted carefully in ER-negative patients. Furthermore, 10-year OS should be interpreted cautiously in patients ≥75 years, T3 tumours and in patients considering endocrine therapy and chemotherapy.
Keywords: Breast cancer; Overall survival; PREDICT; Population-based study; Prediction model; Validation.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.Lancet Oncol. 2009 Nov;10(11):1070-6. doi: 10.1016/S1470-2045(09)70254-2. Epub 2009 Oct 2. Lancet Oncol. 2009. PMID: 19801202
-
Validation of the online prediction model CancerMath in the Dutch breast cancer population.Breast Cancer Res Treat. 2019 Dec;178(3):665-681. doi: 10.1007/s10549-019-05399-2. Epub 2019 Aug 30. Breast Cancer Res Treat. 2019. PMID: 31471837
-
[The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].Ned Tijdschr Geneeskd. 1998 Aug 1;142(31):1772-8. Ned Tijdschr Geneeskd. 1998. PMID: 9856143 Dutch.
-
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8. J Clin Oncol. 2016. PMID: 26858339 Free PMC article. Review.
-
Predicting endocrine therapy responsiveness in breast cancer.Oncology (Williston Park). 2009 Feb;23(2):133-42. Oncology (Williston Park). 2009. PMID: 19323294 Review.
Cited by
-
Insights into the performance of PREDICT tool in a large Mainland Chinese breast cancer cohort: a comparative analysis of versions 3.0 and 2.2.Oncologist. 2024 Aug 5;29(8):e976-e983. doi: 10.1093/oncolo/oyae164. Oncologist. 2024. PMID: 38943540 Free PMC article.
-
Leveraging Digital Twins for Stratification of Patients with Breast Cancer and Treatment Optimization in Geriatric Oncology: Multivariate Clustering Analysis.JMIR Cancer. 2025 May 23;11:e64000. doi: 10.2196/64000. JMIR Cancer. 2025. PMID: 40408774 Free PMC article.
-
myBeST-A Web-Based Survival Prognostic Tool for Women with Breast Cancer in Malaysia: Development Process and Preliminary Validation Study.Int J Environ Res Public Health. 2023 Feb 8;20(4):2985. doi: 10.3390/ijerph20042985. Int J Environ Res Public Health. 2023. PMID: 36833678 Free PMC article.
-
Validation of PREDICT Version 2.2 in a Retrospective Cohort of Indian Women With Operable Breast Cancer.JCO Glob Oncol. 2023 Sep;9:e2300114. doi: 10.1200/GO.23.00114. JCO Glob Oncol. 2023. PMID: 38085062 Free PMC article.
-
A comparative analysis of recurrence risk predictions in ER+/HER2- early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast.Breast Cancer Res Treat. 2022 Nov;196(2):299-310. doi: 10.1007/s10549-022-06729-7. Epub 2022 Sep 10. Breast Cancer Res Treat. 2022. PMID: 36085534 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical